Companies that eschew drug discovery in favor of in-licensing have captured a lot of attention and investment over the past few years. But are these young companies really chasing a sustainable business model?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Bob Crimi
References
Sampaio, E.P. et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703 (1991).
Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thiel, K. Goodbye Columbus! New NRDOs forego discovery. Nat Biotechnol 22, 1087–1092 (2004). https://doi.org/10.1038/nbt0904-1087
Issue Date:
DOI: https://doi.org/10.1038/nbt0904-1087
This article is cited by
-
Wasting cash—the decline of the British biotech sector
Nature Biotechnology (2009)
-
Minimizing leakage of value from R&D alliances
Nature Reviews Drug Discovery (2007)
-
Systems Biology, Incorporated?
Nature Biotechnology (2006)
-
A very firm handshake: biotech's growing negotiating power
Nature Biotechnology (2005)
